Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

Major Program

Supportive Care and Symptom Management

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Completed

NCT ID

NCT01503515

This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.

Intervention

Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole

Condition

Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm

Investigators

Christopher C Dvorak

See list of participating sites